Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 2538 • ACR Convergence 2023
Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Pin-Chia Huang¹, Debby Cheng², Megan H Noe³, Jui-En Lo⁴, Steven T Chen³ and Kevin Sheng-Kai Ma⁵, ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²Harvard Medical School, Boston, MA, ³Department of Dermatology, Massachusetts General Hospital, Boston, MA, ⁴Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis and type 2 diabetes mellitus (T2D) may share common underlying pathophysiology, in which the pathogenesis of psoriasis is mediated by NOD-like receptor family…
Abstract Number: 0853 • ACR Convergence 2023
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Shruthi Srivatsan¹, Zachary Williams¹, Claire Cook¹, Xiaoqing Fu¹, Naomi Patel¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…
Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Jingyi Zhang¹, Ted R Mikuls³, Brian LaMoreaux⁴, Lissa Padnick-Silver⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴Horizon Therapeutics, Deerfield, IL
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Dinesh Khanna¹, Christopher Denton², Masataka Kuwana³, Daniel Furst⁴, Suiyuan Huang¹, Barbara White⁵ and Robert Spiera⁶, ¹University of Michigan, Ann Arbor, MI, ²University College London, London, United Kingdom, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴University of California Los Angeles, Los Angeles, CA, ⁵SFJ Pharmaceuticals, Towson, MD, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…
Abstract Number: 1582 • ACR Convergence 2023
Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data
Bryant England¹, Joshua Baker², Michael George², Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jorge Rojas Jr³, Brian Sauer⁴, Grant Cannon⁵, Jeffrey R Curtis⁶ and Ted R Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
Abstract Number: 0136 • ACR Convergence 2023
The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use
Sophie Do, Jennifer Du, Jaejin An, Jim Wang and Antony Lin, Kaiser SCAL, Fontana, CA
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used for the treatment of various autoimmune diseases. The medication is generally well-tolerated. However, long-term use after 5 years may…
Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Ye Liu¹, Tarun Arora², S. Bobo Tanner³ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
Abstract Number: 0147 • ACR Convergence 2023
Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study
S. Reza Jafarzadeh¹, Matthew Baker², Christine E. Peloquin³, William H. Robinson⁴ and David Felson³, ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Stanford University, Menlo Park, CA, ³Boston University, Boston, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Joint injuries frequently lead to post-traumatic osteoarthritis (OA), a disabling condition often affecting young adults, impacting their quality of life and creating substantial economic…
Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Romain Aymon¹, Denis Mongin², Burkhard Leeb³, Monika Mustak-Blagusz⁴, Jakub Závada⁵, Karel Pavelka⁶, Dan Nordstrom⁷, Nina Trokovic⁸, Florenzo Iannone⁹, Catalin Codreanu¹⁰, Ziga Rotar¹¹, Tore Kvien¹², Sella Provan¹³, Manuel Enrique Pombo Suarez¹⁴, Fernando Alonso¹⁵, Fatos Onen¹⁶, Nevsun Inanc¹⁷, Louis Coupal¹⁸, Denis Choquette¹⁹, Galina Lukina²⁰, Ori Elkayam²¹, Victoria Furer²¹, Ana Maria Rodrigues²², Delphine COURVOISIER²³, Axel Finckh²⁴, Michael Nissen² and Kim Lauper²⁵, ¹Geneva University Hospitals, Collonges-sous-Salève, France, ²Geneva University Hospitals, Geneva, Switzerland, ³BioReg, Stockerau, Austria, ⁴BioReg, Vienna, Austria, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University of Helsinki, Helsinki, Finland, ⁹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁰Center for Rheumatic Diseases, Bucharest, Romania, ¹¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹³Diakonhjemmet Hospital, Oslo, Norway, ¹⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹⁵Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²⁰Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, ²¹Tel Aviv Medical Center, Tel Aviv, Israel, ²²Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²⁴HUG, Geneva, Switzerland, ²⁵Geneva University Hospitals, Genève, Switzerland
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Vibeke Strand¹, Prajakta Masurkar², Jennifer Reckleff³, Taylor Schwartz⁴, Alison Silverstein⁴, Jennifer Osborne⁴, Josie Lloyd⁴, Brian Leinwand⁴, Elaine Karis⁵, Fatima Barbar-Smiley⁶ and Karen Costenbader⁷, ¹Stanford University, Portola Valley, CA, ²Amgen, Inc., Atlanta, GA, ³Amgen, Inc., Westlake Village, CA, ⁴Inovalon Insights, Bowie, MD, ⁵Amgen, Inc., Colts Neck, NJ, ⁶Amgen, Inc., Dublin, OH, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
Abstract Number: 1812 • ACR Convergence 2023
Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Laura Daniel¹, Alyson Dickson², Puran Nepal¹, Otis Wilson³, Adriana Hung², Dale Plummer³, William Dupont³, Katherine Murray³, C. Michael Stein², Wayne Ray³ and Cecilia Chung⁴, ¹University of Miami, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴University of Miami, Miami, FL
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the FDA for the treatment of different forms of chronic pain. Because of its adrenergic activity,…
Abstract Number: 0247 • ACR Convergence 2023
Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
Sheryl Kluberg¹, Andrew Simon², Sarah Alam², Alexander Peters², Casie Horgan², Dongdong Li², Érick Moyneur³, Richard Platt², Cheryl N McMahill-Walraven⁴, Djeneba Audrey Djibo⁴, Qianli Ma⁵, Mano Selvan⁵, Claire Pernar⁶, Najat Ziyadeh⁶, Aziza Jamal-Allial⁷, Kimberly Daniels⁷, O’Mareen Spence⁸, Driss Oraichi⁸, Harry Seifert⁸, Valentine Franck⁹, Susan Gamble⁸ and Huifeng Yun⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Newton, MA, ²Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ³StatLog Inc, Quebec City, QC, Canada, ⁴CVS Health, Blue Bell, PA, ⁵Humana Healthcare Research, Inc., Louisville, KY, ⁶Optum, Baltimore, MD, ⁷Carelon Research, Boston, MA, ⁸GlaxoSmithKline, Rockville, MD, ⁹GlaxoSmithKline, Wavre, Belgium
Background/Purpose: Pre-licensure clinical trials for recombinant zoster vaccine (RZV) identified more frequent gout diagnoses among recipients of RZV than placebo; however, these trials were not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.